2024

1. Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

   Journal of Clinical Lipidology

2. Advances in heart failure management

   Medicina Clinica, Vol. 163, Núm. 1, pp. 32-39

3. Applicability of heart failure clinical practice guidelines in low- and middle-income countries

   European Journal of Heart Failure

4. Atrial secondary tricuspid regurgitation: Pathophysiology, definition, diagnosis, and treatment

   European Heart Journal, Vol. 45, Núm. 11, pp. 895-911

5. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation: 1-Year Follow-Up Outcomes

   JACC: Cardiovascular Interventions, Vol. 17, Núm. 1, pp. 60-72

6. Cardiac wasting and cancer

   European Heart Journal

7. Characteristics and Management of Patients With Cancer and Atrial Fibrillation: The BLITZ-AF Cancer Registry

   JACC: Advances, Vol. 3, Núm. 7

8. Characterizing the “iceberg peak” in valvular heart disease: Outcomes and costs of in-hospital procedures in Spain

   REC: CardioClinics, Vol. 59, Núm. 4, pp. 285-294

9. Circulating miRNA in functional tricuspid regurgitation. Unveiling novel links to heart failure: A pilot study

   ESC Heart Failure, Vol. 11, Núm. 4, pp. 2272-2286

10. Combined Impact of Residual Mitral Regurgitation and Gradient After Mitral Valve Transcatheter Edge-to-Edge Repair

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 21, pp. 2530-2540

11. Concomitant Transcatheter Tricuspid Annuloplasty and Edge-to-Edge Repair in Torrential Tricuspid Regurgitation

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 1, pp. 99-100

12. Electroporation saves the day again: Pulsed-field ablation for phrenic nerve-sparing in right atrial tachycardia

    Journal of Cardiovascular Electrophysiology, Vol. 35, Núm. 10, pp. 2071-2075

13. Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

    European Journal of Heart Failure, Vol. 26, Núm. 1, pp. 18-33

14. Evaluating Mitral TEER in the Management of Moderate Secondary Mitral Regurgitation Among Heart Failure Patients

    JACC: Heart Failure

15. Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2

    Journal of the American College of Cardiology

16. How to improve patient outcomes following TAVI in 2024? Recent advances

    Kardiologia Polska, Vol. 82, Núm. 7-8, pp. 696-701

17. Is DOAC the preferred oral anticoagulation therapy after TAVI?

    Revista Espanola de Cardiologia

18. Long-term right heart remodeling after transcatheter tricuspid annuloplasty assessed by cardiac tomography

    Journal of Cardiovascular Computed Tomography

19. NOS3 prevents MMP-9, and MMP-13 induced extracellular matrix proteolytic degradation through specific microRNA-targeted expression of extracellular matrix metalloproteinase inducer in hypertension-related atherosclerosis

    Journal of Hypertension, Vol. 42, Núm. 4, pp. 685-693

20. Percutaneous Closure of Incomplete Surgical Left Atrial Appendage Ligation: Success Begins With the Decision to Try

    Journal of Invasive Cardiology, Vol. 36, Núm. 9